secwatch.observer — SEC 8-K summary
======================================

Issuer:     SERA PROGNOSTICS, INC. (SERA)
CIK:        0001534969
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0001534969-22-000122
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sera Prognostics Q2 net loss widens to $11.5M; cash runway extended to 2026
---------------------------------------------------------------------------

- Revenue of $78K, up from $20K in Q2 2021, but operating expenses rose to $11.8M from $7.4M.
- Net loss of $11.5M ($0.29/share) vs $6.3M a year ago; cash & securities at $121M as of June 30.
- PreTRM test now collects blood at 18-20 weeks; sensitivity ~90%, NPV 99% for preterm risk.
- Company streamlined operations to fund operations into 2026 without additional financing.
- Contracted several new self-insured employer plans for PreTRM testing as an advanced pregnancy benefit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534969/000153496922000122/0001534969-22-000122-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534969/000153496922000122/sera-20220810.htm
  HTML page:      https://secwatch.observer/filing/0001534969-22-000122

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer